Cynosure Company Profile (NASDAQ:CYNO)

About Cynosure (NASDAQ:CYNO)

Cynosure logoCynosure, Inc. develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women's health. The Company also markets radiofrequency (RF), energy-sourced medical devices for surgical applications, such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. The Company sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names. Its product portfolio includes single energy source systems, as well as workstations that incorporate two or more different types of lasers or light-based technologies.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:CYNO
  • CUSIP: 23257720
  • Web:
Average Prices:
  • 50 Day Moving Avg: $62.47
  • 200 Day Moving Avg: $50.89
  • 52 Week Range: $39.90 - $66.65
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 32.50
  • P/E Growth: 0.00
  • Net Margins: 0.70%
  • Return on Equity: 0.75%
  • Return on Assets: 0.59%
  • Debt-to-Equity Ratio: 0.04%
  • Current Ratio: 3.28%
  • Quick Ratio: 2.54%
  • Average Volume: 1.17 million shs.
  • Beta: 1.65

Frequently Asked Questions for Cynosure (NASDAQ:CYNO)

What is Cynosure's stock symbol?

Cynosure trades on the NASDAQ under the ticker symbol "CYNO."

How were Cynosure's earnings last quarter?

Cynosure, Inc. (NASDAQ:CYNO) released its quarterly earnings results on Tuesday, July, 26th. The company reported $0.36 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.29 by $0.07. The company earned $110.30 million during the quarter, compared to analyst estimates of $101.31 million. Cynosure had a return on equity of 0.75% and a net margin of 0.70%. The firm's revenue was up 31.8% on a year-over-year basis. During the same quarter last year, the business posted $0.30 earnings per share. View Cynosure's Earnings History.

Where is Cynosure's stock going? Where will Cynosure's stock price be in 2017?

7 equities research analysts have issued twelve-month target prices for Cynosure's stock. Their predictions range from $40.00 to $66.00. On average, they expect Cynosure's stock price to reach $58.33 in the next twelve months. View Analyst Ratings for Cynosure.

Who are some of Cynosure's key competitors?

How do I buy Cynosure stock?

Shares of Cynosure can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cynosure's stock price today?

One share of Cynosure stock can currently be purchased for approximately $65.97.

MarketBeat Community Rating for Cynosure (NASDAQ CYNO)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  212 (Vote Outperform)
Underperform Votes:  108 (Vote Underperform)
Total Votes:  320
MarketBeat's community ratings are surveys of what our community members think about Cynosure and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cynosure (NASDAQ:CYNO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $58.33 (11.58% downside)

Analysts' Ratings History for Cynosure (NASDAQ:CYNO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/28/2017AegisReiterated RatingHold$66.00N/AView Rating Details
2/16/2017Northland SecuritiesReiterated RatingOutperform$60.00N/AView Rating Details
2/14/2017Northcoast ResearchUpgradeSell -> NeutralN/AView Rating Details
2/14/2017Maxim GroupDowngradeBuy -> Hold$66.00N/AView Rating Details
10/28/2016Leerink SwannReiterated RatingOutperform$63.00 -> $60.00N/AView Rating Details
10/26/2016Stifel NicolausReiterated RatingBuy$62.00 -> $58.00N/AView Rating Details
10/24/2016Brean CapitalReiterated RatingBuyN/AView Rating Details
(Data available from 9/21/2015 forward)


Earnings History for Cynosure (NASDAQ:CYNO)
Earnings by Quarter for Cynosure (NASDAQ:CYNO)
Earnings History by Quarter for Cynosure (NASDAQ CYNO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/7/2017Q416$0.41$0.44$119.97 million$122.10 millionViewListenView Earnings Details
10/25/2016Q316$0.28$0.29$101.11 million$106.40 millionViewListenView Earnings Details
7/26/2016Q216$0.29$0.36$101.31 million$110.30 millionViewListenView Earnings Details
4/26/2016Q116$0.14$0.19$85.78 million$94.70 millionViewListenView Earnings Details
2/9/2016Q415$0.36$0.42$95.01 million$102.40 millionViewListenView Earnings Details
10/27/2015Q315$0.18$0.21$76.68 million$78.40 millionViewListenView Earnings Details
7/28/2015Q215$0.27$0.30$82.71 million$83.70 millionViewListenView Earnings Details
5/5/2015Q1$0.17$0.15$70.87 million$74.90 millionViewListenView Earnings Details
2/10/2015Q414$0.39$0.36$83.01 million$86.30 millionViewListenView Earnings Details
10/28/2014Q314$0.24$0.25$69.94 million$71.50 millionViewListenView Earnings Details
7/29/2014Q214$0.30$0.32$71.15 million$72.60 millionViewListenView Earnings Details
5/6/2014Q1$0.23$0.19$64.70 million$62.00 millionViewListenView Earnings Details
2/12/2014Q413$0.19$0.39$67.80 million$74.50 millionViewListenView Earnings Details
10/29/2013Q313$0.19$0.23$61.60 million$60.70 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.20$0.29$46.96 million$50.09 millionViewListenView Earnings Details
4/30/2013Q1 2013$0.13$0.12$38.51 million$10.70 millionViewListenView Earnings Details
2/12/2013Q4 2012$0.23$0.27$40.98 million$47.70 millionViewListenView Earnings Details
10/23/2012$0.12$0.25ViewN/AView Earnings Details
7/24/2012$0.12$0.20ViewN/AView Earnings Details
5/1/2012($0.02)$0.06ViewN/AView Earnings Details
2/14/2012$0.05$0.08ViewN/AView Earnings Details
10/25/2011$0.04($0.06)ViewN/AView Earnings Details
5/3/2011($0.05)($0.15)ViewN/AView Earnings Details
2/15/2011($0.03)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cynosure (NASDAQ:CYNO)
2017 EPS Consensus Estimate: $1.63
2018 EPS Consensus Estimate: $2.02
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.23$0.26$0.24
Q2 20173$0.40$0.44$0.43
Q3 20173$0.38$0.42$0.40
Q4 20173$0.51$0.61$0.57
Q1 20181$0.34$0.34$0.34
Q2 20181$0.51$0.51$0.51
Q3 20181$0.50$0.50$0.50
Q4 20181$0.67$0.67$0.67
(Data provided by Zacks Investment Research)


Dividend History for Cynosure (NASDAQ:CYNO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Cynosure (NASDAQ:CYNO)
Insider Ownership Percentage: 2.90%
Insider Trades by Quarter for Cynosure (NASDAQ:CYNO)
Institutional Ownership by Quarter for Cynosure (NASDAQ:CYNO)
Insider Trades by Quarter for Cynosure (NASDAQ:CYNO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/22/2016Douglas J DelaneyVPSell7,875$45.00$354,375.00View SEC Filing  
11/22/2016Michael R DavinChairmanSell16,284$45.00$732,780.00View SEC Filing  
8/30/2016Brian M BarefootDirectorSell21,000$51.66$1,084,860.00View SEC Filing  
8/15/2016Michael R DavinChairmanSell12,062$53.35$643,507.70View SEC Filing  
8/15/2016Timothy W BakerCFOSell5,834$53.35$311,243.90View SEC Filing  
8/11/2016Michael R DavinChairmanSell4,222$53.18$224,525.96View SEC Filing  
8/11/2016Timothy W BakerCFOSell2,041$53.19$108,560.79View SEC Filing  
5/13/2016Douglas J DelaneyVPSell12,299$46.60$573,133.40View SEC Filing  
5/13/2016Michael R DavinCEOSell26,271$46.59$1,223,965.89View SEC Filing  
5/13/2016Timothy W BakerCFOSell12,451$46.60$580,216.60View SEC Filing  
4/18/2016Douglas J DelaneyVPSell15,890$45.01$715,208.90View SEC Filing  
4/18/2016Michael R DavinCEOSell74,729$45.31$3,385,970.99View SEC Filing  
4/18/2016Timothy W BakerCFOSell14,008$45.02$630,640.16View SEC Filing  
4/14/2016Douglas J DelaneyVPSell24,488$45.02$1,102,449.76View SEC Filing  
4/14/2016Michael R DavinCEOSell61,377$45.01$2,762,578.77View SEC Filing  
4/14/2016Timothy W BakerCFOSell39,857$45.02$1,794,362.14View SEC Filing  
4/13/2016Michael R DavinCEOSell72$45.00$3,240.00View SEC Filing  
4/6/2016Douglas J DelaneyVPSell4,408$45.08$198,712.64View SEC Filing  
4/6/2016Michael R DavinCEOSell4,869$45.11$219,640.59View SEC Filing  
4/6/2016Timothy W BakerCFOSell4,413$45.08$198,938.04View SEC Filing  
4/4/2016Douglas J DelaneyVPSell66,626$45.47$3,029,484.22View SEC Filing  
4/4/2016Michael R DavinCEOSell66,259$45.61$3,022,072.99View SEC Filing  
4/4/2016Timothy W BakerCFOSell53,297$45.60$2,430,343.20View SEC Filing  
12/31/2015Michael R. DavinCEOSell200$45.00$9,000.00View SEC Filing  
12/31/2015Timothy W. BakerCFOSell100$45.00$4,500.00View SEC Filing  
6/1/2015Ettore V BiagioniDirectorSell24,000$36.25$870,000.00View SEC Filing  
5/20/2015Douglas J DelaneyVPSell89,000$38.01$3,382,890.00View SEC Filing  
5/20/2015Michael R DavinCEOSell151,000$38.07$5,748,570.00View SEC Filing  
4/23/2015Michael R DavinCEOSell6,991$33.04$230,982.64View SEC Filing  
4/10/2015Michael R DavinCEOSell44,677$33.01$1,474,787.77View SEC Filing  
4/9/2015Douglas J DelaneyVPSell28,335$33.01$935,338.35View SEC Filing  
4/9/2015Michael R DavinCEOSell70,000$32.00$2,240,000.00View SEC Filing  
4/8/2015Douglas J DelaneyVPSell45,000$32.00$1,440,000.00View SEC Filing  
1/9/2015Ettore V BiagioniDirectorSell12,000$30.09$361,080.00View SEC Filing  
12/2/2014Ettore V BiagioniDirectorSell2,500$28.00$70,000.00View SEC Filing  
11/24/2014Ettore V BiagioniDirectorSell5,000$27.28$136,400.00View SEC Filing  
11/5/2013Marina HatsopoulosDirectorBuy3,000$22.60$67,800.00View SEC Filing  
9/5/2012Douglas J DelaneyVPSell16,904$27.65$467,395.60View SEC Filing  
9/5/2012Michael R DavinCEOSell16,770$27.65$463,690.50View SEC Filing  
9/5/2012Timothy W BakerCFOSell16,854$27.65$466,013.10View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Cynosure (NASDAQ:CYNO)
Latest Headlines for Cynosure (NASDAQ:CYNO)
DateHeadline logoTrump's Pick for Federal Reserve's Top Regulator Just Won This Battle - September 8 at 6:07 PM logoCutera Strengthens Leadership Team with Two Key Executive Appointments - Nasdaq - August 21 at 10:26 PM logoGlobal Aesthetic Laser Market 2017-2023 - Leading Companies Cynosure, Lumenis, Cutera, Alma Lasers & Sciton - Research and Markets - August 19 at 4:57 PM logoGlobal Aesthetic Laser Market 2017-2023 - Leading Companies ... - Business Wire (press release) - August 18 at 5:44 PM logoAnalyzing Derma Sciences (DSCI) & Cynosure (CYNO) - August 3 at 8:29 AM logoHologic (HOLX) Q3 2017 Results - Earnings Call Transcript - August 2 at 11:37 PM logoHologic Announces Financial Results for Third Quarter of Fiscal 2017 - August 2 at 6:37 PM logoTrump's Wall Street Watchdogs to Shed Millions Invested in Banks - Bloomberg - July 25 at 5:42 PM logoWhat's in the Offing for Hologic (HOLX) in Q3 Earnings? - Nasdaq - July 24 at 10:46 AM logoMedical Aesthetics Market to Reach $19.4 Billion by 2023: P&S Market Research - July 19 at 11:56 PM logoHologic: Growth Cheaply Priced - Seeking Alpha - July 16 at 9:42 AM logoRevolving Door Spins Ex-Carlyle Deal-Maker Into Key Fed Role - July 12 at 11:27 PM logoTrump's Fed Nominee Has History of Benefiting From Bailouts - New York Times - July 12 at 6:24 PM logoCynosure, Inc. (CYNO) Given Consensus Rating of "Hold" by Brokerages - June 23 at 10:58 PM logoHologic Receives Expanded FDA 510(k) Clearance to Market Cynosure's SculpSure ... - June 15 at 6:33 PM logoGlobal Cellulite Treatment Market - Industry Forecast to 2025 - Analysis By Treatment, End User & Geography - Research and Markets - June 8 at 5:39 PM logoGlobal Anti-Aging Market Size & Trends Will Reach $216.52 Billion by 2021: Zion Market Research - June 5 at 11:54 AM logoCynosure, Inc. (CYNO) Given Consensus Rating of "Hold" by Analysts - May 29 at 9:06 PM logoGlobal Medical Aesthetics Market to Reach $13 Billion by 2021 - Analysis By Product, End User & Region - Research and Markets - May 29 at 4:45 PM logoAsia-Pacific Aesthetic Lasers and Energy Devices Market Outlook to 2023 - May 16 at 4:39 PM logoMedical Aesthetic Devices Market - Middle East and North Africa Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024 - May 11 at 10:18 PM logoCynosure (CYNO) Earning Somewhat Favorable News Coverage, Analysis Finds - May 3 at 3:28 PM logoAesthetics Combination Therapy Market Revenues to Reach US$ 3.69 Bn by 2024 - Persistence Market Research - May 3 at 8:46 AM logoCynosure, Inc. (CYNO) Receives Average Rating of "Hold" from Brokerages - May 2 at 10:48 PM logoCynosure (CYNO) Receives Media Impact Rating of 0.12 - April 29 at 9:35 PM logoLiposuction Devices - Global Market Outlook (2016-2022) - April 27 at 5:10 PM logoSomewhat Negative News Coverage Very Unlikely to Impact Cynosure (CYNO) Stock Price - April 26 at 1:52 PM logoCynosure (CYNO) Earning Somewhat Positive News Coverage, Analysis Finds - April 23 at 2:09 PM logoCynosure, Inc. (CYNO) to Release Earnings on Monday - April 21 at 11:26 PM logoCynosure (CYNO) Receiving Positive Media Coverage, Report Shows - April 20 at 8:59 PM logoTrump to Nominate Quarles for Fed's Top Regulatory Post, Source Says - April 18 at 12:07 PM logoSomewhat Negative Press Coverage Likely to Impact Cynosure (CYNO) Stock Price - April 15 at 2:13 PM logoSouth Korea Aesthetic Lasers and Energy Devices Market Outlook to 2023 - April 11 at 4:29 PM logoGermany Aesthetic Lasers and Energy Devices Market Outlook to 2023 - April 10 at 4:30 PM logoCynosure, Inc. (CYNO) Receives Average Recommendation of "Hold" from Brokerages - April 5 at 5:19 PM logoAegis Reiterates "Hold" Rating for Cynosure, Inc. (CYNO) - March 28 at 11:23 AM logoCynosure, Inc. (CYNO) Short Interest Down 29.3% in March - March 28 at 8:26 AM logoForm 4 CYNOSURE INC For: Mar 22 Filed by: Hatsopoulos Marina - - March 25 at 11:01 AM logoForm 4 CYNOSURE INC For: Mar 22 Filed by: Hatsopoulos Marina - March 24 at 9:55 PM logoForm SC 14D9/A CYNOSURE INC Filed by: CYNOSURE INC - March 24 at 4:53 PM logoDermatology Devices Market Worth $25 Billion by 2025 | CAGR: 12.7%: Grand View Research, Inc. - March 23 at 5:11 PM logoCYNOSURE INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure t - March 23 at 5:11 PM logoMRLB U.S. Sales Jump 38% As Aesthetic Market Heats Up - March 22 at 4:46 PM logoCynosure, Inc. (CYNO) Downgraded by Aegis to Hold - March 21 at 7:10 AM logoAegis Lowers Cynosure, Inc. (CYNO) to Hold - March 18 at 8:45 AM logoCynosure, Inc. (CYNO) Short Interest Update - March 11 at 7:33 AM logoCynosure, Inc. (CYNO) Given Average Rating of “Hold” by Analysts - March 10 at 12:38 PM logoScar Treatment Market Worth $34.5 Billion by 2025 | Growth Rate: 9.7%: Grand View Research, Inc. - March 8 at 5:23 PM logoCYNOSURE INC Financials - March 4 at 5:02 PM logoForm SC 14D9/A CYNOSURE INC Filed by: CYNOSURE INC - - March 4 at 2:49 AM



Cynosure (CYNO) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by Staff